Veminsyn

Company Profile

Founded in 2021 by a team of PhDs from Peking University and Tsinghua University,Veminsyn is an innovative company in the field of synthetic biology. The company is based on AI+biotechnologyAt the core of the company, it has constructed the world's largest database of bioactives, and through microbial fermentation, plant cell culture and other technologies, it has developed innovative raw materials, such as XVII collagen and blossom guaiac tissue extract, to serve the beauty, medical beauty and health industries. Its core advantage lies in the whole chain technology of "AI discovery - intelligent evaluation - low carbon production". It owns a GMP-grade factory in Suzhou, which realizes a carbon emission reduction of 30% and has been certified by 158 national raw material filing certificates. Customers include L'Oreal, Pelletier and other top brands, and after completing the B+ round of financing in 2025, we will accelerate the upgrading of AI platform and globalization layout. With the rapid growth of the recombinant collagen market, Unnamed Pickup is expected to become a leading company in the field of bio-intelligence by virtue of its technological barriers and industrial synergy capabilities.

Milestones

1. 2021::
   • In May, the company was formally established with a founding team from the State Key Laboratory of Peking University and Tsinghua University.
   • In November, completed angel round financing (led by Jiacheng Capital and Zhenge Fund) and launched Pre-A round financing (led by Hony Capital).
   • In December, Vemin Lab was jointly established with Peking University, focusing on biosynthetic technology research and development.
2. 2022::
   • In July, Hangzhou R&D Center was listed for operation to accelerate raw material development.
   • In October, completed A round of financing (led by CITIC Capital), the funds were used for database construction and capacity expansion.
3. 2023::
   • In March, the GMP-grade plant in Suzhou was put into operation, realizing the large-scale production of collagen and other raw materials.
   • In December, completed A+ round of financing (led by NAI Group) and published the first high-impact paper in the industry (featured in the journal Cell).
4. 2024::
   • In June, it was approved the first recombinant collagen Su Device Class II certificate, entering the field of medical aesthetic devices.
   • In October, its medical beauty brand "Light Original Xin Sheng" was officially unveiled, launching XVII collagen products.
5. 2025::
   • In February, our subsidiary Suzhou Jiguang Pharmaceutical's "Recombinant Collagen Wound Dressing" was approved to be listed on the market.
   • In May, it completed a strategic round of financing of nearly 100 million yuan (co-invested by L'Oreal and NAIAS Group) and entered into a strategic cooperation.
   • In September, it completed tens of millions of yuan of B+ round financing (Huatai Kingsley and HaiBang Investment injection) for AI technology platform upgrade and globalization layout.

Products & Services

The product matrix covers three main categories:

1. Small molecule active collagen::
   • The core products include XVII, III, IV, VII collagen, using the "original cut collagen" technology, 100% humanized, structurally complete, can repair the aging of the basement membrane band.
   • Representative product: Kohara Xinsheng® Recombinant XVII Collagen, which is free of endotoxin and exogenous sequence contamination through the fermentation technology of Saccharomyces cerevisiae.
2. plant cell culture::
   • Utilizing "semi-solid tissue culture technology", breaking through the limitation of rare plant resources, the active retention rate of the extract reached 98%, and the pollution was reduced by 50%.
   • Representative product: Blossom Healing Tissue Extract (the first new raw material based on this technology filed in China).
3. Collagen and Medical Devices::
   • Medical aesthetic products: collagen filler, wound dressing (Su Meizhi quasi 20252140245).
   • Functional Food Ingredients: Tianshan Snow Lotus Root Extract (Coming Soon)

Service model::

• self-research: Developing innovative ingredients through an AI + biotech platform.
• CRDMOIt provides customized raw material development and OEM services for downstream brands in the form of contract R&D and production organization, and its customers include Perrier, Huaxi Bio, L'Oreal and other headline companies.

core competence

1. technical barrier::
   • The world's largest database of bioactives: Covering 30 billion molecular data, AI algorithm realizes targeted screening, and over 200 bioactives have been discovered and applied.
   • Multidimensional biosynthesis platform: Integration of microbial cells, plant healing tissues, cell-free synthesis and other technologies, original "semi-solid healing tissue culture technology", to enhance the activity of rare ingredients.
   • Intelligent Evaluation SystemThe non-invasive transdermal testing platform based on Raman spectroscopy and the dual platform of AI efficacy evaluation solve the problems of in vivo penetration and efficacy consistency of raw materials.
2. Capacity and Commercialization::
   • Suzhou GMP-grade factory realizes low-carbon production of collagen and other raw materials, reducing carbon emissions by 30%.
   • We have passed 158 certifications of raw materials filed by the State Drug Administration and served more than 100 customers, including international giants L'Oreal, Procter & Gamble and Unilever.
3. Capital and Industry Recognition::
   • Completed 5 rounds of financing, with investors including CITIC Capital, Hony Capital, Zhenge Fund and other head institutions.
   • Entered into a strategic partnership with L'Oreal to integrate their resources in AI design and skin biology to accelerate the development of high-performance ingredients.

development prospect

1. market opportunity::
   • China collagen market size is expected to reach 71.9 billion yuan in 2025, with recombinant collagen leading the segment with a CAGR of 42.4%.
   • The blurring of the boundaries between medical beauty and skin care products has led to an increase in the demand for "machine-named" products, and the product layout of Unnamed Gleam is in line with the industry trend.
2. strategic direction::
   • Technology deepening: Upgrade AI platform to expand biomaterial application scenarios (e.g., functional food, medical).
   • Globalization: Promote the globalization of the application of core raw material technologies through transnational collaborative innovation.
   • expansion of production capacity: Construction of the second phase of the Suzhou plant to increase the production capacity of collagen and other raw materials.
3. Challenges and risks::
   • Biosynthesis technology iterates at a rapid pace and requires continuous investment in R&D to stay ahead of the curve.
   • Tightening regulation of the medical aesthetic industry requires ensuring product compliance.